Table 2.
Approved/investigational drug therapies for alopecia areata or alopecia universalis.
Drug (Trade name) | Structure | M, F, Both, animal | Class/route | Mechanism | Ref |
---|---|---|---|---|---|
Hydrocortisone (Cortizone) | ![]() |
Both; approved | Corticosteroid; topical; intradermal injection, oral | Anti-inflammatory, immunosuppressive | [155] |
Clobetasol propionate (Temovate) | ![]() |
Both; clinical trial | ‘Strong’ corticosteroid; topical; intradermal injection | Anti-inflammatory, immunosuppressive | [155] |
Dinitrochlorobenzene | ![]() |
Both | Local irritant; topical | Triggering sensitization counteracting autoreactive T cells | [110] |
Squaric acid dibutylester | ![]() |
Both | Local irritant; topical | Triggering sensitization counteracting autoreactive T cells | [156] |
Diphenylcyclopropenone (Diphencyprone) | ![]() |
Both | Local irritant; topical | Triggering sensitization counteracting autoreactive T cells | [157] |
8-Methoxypsoralen and UVA (PUVA) | ![]() |
Both | Photochemotherapy, drug-light combination; topical | Kills autoreactive T cells; induces tolerogenic dendritic cells | [158] |
Sulfasalazine (Azulfidine) | ![]() |
Both; clinical trial | Developed as antibiotic; oral | Anti-inflammatory immunomodulator | [159] |
Adalimumab (Humira) | F; case report | Recombinant human IgG1 MoAb against TNFα; s.c. injection | Anti-inflammatory; inhibits T cells | [160] | |
Alefacept (Amevive) | F; case report | 1-92-LFA-3 (human) fusion protein with Ig G1 | Inhibits T cells | [161] | |
Ruxolitinib (Jakavi) | ![]() |
Case reports, mice | JAK inhibitor; topical, systemic | Affects downstream signaling of IFN-γ; and GC cytokine receptors | [101] |
Tofacitinib (Jakvinus) | ![]() |
Mice | JAK inhibitor; topical, systemic | Affects downstream signaling of IFN-γ and GC cytokine receptors | [101] |